**3.1 Epidemiology**

The clinical spectrum of melanocytic tumors of the conjunctiva constitutes about 53% of all conjunctival tumors. The reported incidence is two cases per million per year, but the incidence is increasing. It usually occurs at a median age of 62 years and is very rare in children [4, 5].

3.Double freeze thaw cryotherapy of the resection edge and the clinically

4.Episcleral plaque brachytherapy if base is involved for more than 3 clock hours. Plaque rotation can be customized depending on the tumor extent.

6. Sentinel lymphangiography is indicated in tumors more than 2 mm and helps

Abnormal proliferation of the melanocytes, spindle, or the epitheloid cells.

1.Metastasis to ipsilateral facial lymph nodes, brain, lung, skin, bone, and liver

2.Multiple recurrences, especially those within the orbit, might require orbital

3. Intraocular and intraorbital involvement may require modified enucleation

5.Overall mortality rate is 25% at 10 years and more than 30% in 15 years [9, 10].

6.The 10 year rate of metastasis is PAM 25%, Nevus 26%, De novo 49% [11]

7.The prognosis can be predicted by the AJCC-TNM staging of conjunctival

8.The factors predictive of metastasis or death are de novo origin, tarsal or

forniceal location, nodular mass, and orbital invasion [11].

5. Interferon and interleukin-2 in combination can be administered in

suspected involved base if it is less than 3 clock hours.

disseminated melanoma [8].

are the most common.

melanoma (**Table 1**).

**35**

exenteration [4].

**3.5 Histopathology**

**3.6 Prognosis**

**Figure 1.**

*Conjunctival melanoma.*

*Ocular Melanoma*

*DOI: http://dx.doi.org/10.5772/intechopen.93760*

in complete removal of the lymph nodes.

and orbital exenteration, respectively.

4.Recurrences after the therapy are 50–70% at 10 years.
